Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730468 · ClinicalTrials.gov registry record
SEP-SEQ Trial - Determining the Etiology of Sepsis Using an Infectious Disease Diagnostic Sequencing Assay
A clinical trial of Sepsis, sponsored by Karius.
- Completed
- Registry status
- 350
- Enrollment target
- 1
- Study location
NCT02730468 is a study of Sepsis that has completed, run by Karius. The registered enrollment target is 350 participants, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02730468, a study of Sepsis, has completed, sponsored by Karius.
- COMPLETED
- Registry status
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the performance of the Karius Infectious Diseases Plasma Sequencing Assay in patients who present to the emergency room with sepsis.
Conditions Studied
Study Locations (1)
California
- Stanford University Hospital - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2016-04 |
| Est. Completion | 2017-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02730468
The ClinicalTrials.gov registry entry for NCT02730468 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower). The listed sponsor is Karius, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 0 interventions.
NCT02730468 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02730468 about?
NCT02730468 is a clinical study titled "SEP-SEQ Trial - Determining the Etiology of Sepsis Using an Infectious Disease Diagnostic Sequencing Assay". The purpose of this study is to evaluate the performance of the Karius Infectious Diseases Plasma Sequencing Assay in patients who present to the emergency room with sepsis.
What is the current status of trial NCT02730468?
This trial is currently completed. The enrollment target is 350 participants. The study started on 2016-04. Estimated completion is 2017-10.
What conditions does trial NCT02730468 study?
This clinical trial studies the following conditions: Sepsis.
Who is sponsoring clinical trial NCT02730468?
This trial is sponsored by Karius, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02730468 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.